Morgan Stanley maintains Immunocore Holdings at Equal-Weight, lowers price target to $42 from $43

Morgan Stanley kept its Equal-Weight rating on Immunocore Holdings but reduced its price target to $42 from $43, a 2.3% decrease. This implies a 37.8% upside from the Nov 12 close of $30.48, according to the bank.

Original reporting
Published Nov 13, 2026, 6:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains Immunocore Holdings at Equal-Weight, lowers price target to $42 from $43 — source image
Decision brief

The 30-second read

$IMCRNeutralLow
01

Why it matters

For traders, the actionable element is the revised valuation view (PT lowered) while the stance (Equal-Weight) remains unchanged.

02

Market read

A modest price-target cut can slightly pressure sentiment, but unchanged rating and lack of new fundamentals keep impact limited.

03

What to watch

The article provides no new fundamental driver (trial data, approvals, guidance), so price action is more likely to be driven by broader biotech sentiment than by this PT change alone.

Relevance 4/10Novelty 3/10Timing: today, as the analyst note/PT change is newly published

Background

The piece is an analyst-maintenance update from Morgan Stanley, not a company disclosure.

Company-level read

Ticker impact

$IMCRNeutralMedium confidence
Context

Morgan Stanley maintained Immunocore at Equal-Weight and cut its price target to $42 from $43, signaling a modest valuation reset for IMCR.

Expected impact

Likely limited downside bias as traders adjust expectations to the lower target, with muted reaction due to no rating change.

Evidence & confidence

A price-target trim without an upgrade or downgrade typically produces small, short-lived sentiment effects rather than a major repricing.

Market effects

Minimal sector read-through, since this is a single-name valuation adjustment with no new clinical, regulatory, or commercial catalyst mentioned.

None indicated.

None indicated.

Counterpoint

Equal-Weight plus a small target reduction may be interpreted as the analyst still sees fair value, limiting the need for traders to cut exposure aggressively.

Key entities

  • Immunocore Holdings

    Subject of the analyst action: maintained Equal-Weight and lowered price target to $42 from $43.

  • Morgan Stanley

    Issued the rating maintenance and price-target reduction described in the article.

Related articles

$IMCRMed

Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary

Immunocore reported a 1.4% YoY revenue decline to $102.22M in Q3 2026, with a widened net loss of $14.22M. U.S. sales fell due to stocking adjustments and fewer sales weeks, partially offset by European and international growth. R&D spending increased, impacting results. KIMMTRAK is approved in 39 countries, and TEBE-AM Phase 3 trial enrollment is complete, with data expected in Q2 2027.